Skip to content
EntityQ7863873· pop 7· linked from 319 articles

Also known as UBP302, UBP 302

UBP-302 is a highly selective kainate receptor antagonist used in the study of many neurological processes. It is active at micromolar concentration within an in vitro preparation and specifically targets the GluK1 (iGluR5) subunit of the receptor. This compound was developed at the University of Bristol.

~1 min read

Encyclopedic overview

1 sections
Contents
  • References

{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443145597 | ImageFile = UBP-302.png | ImageClass = skin-invert-image | ImageSize = 240px | SystematicName=2-({3-[(2S)-2-Amino-2-carboxyethyl]-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl}methyl)benzoic acid | OtherNames= |Section1= |Section2= |Section3= }}

UBP-302 is a highly selective kainate receptor antagonist used in the study of many neurological processes. It is active at micromolar concentration within an in vitro preparation and specifically targets the GluK1 (iGluR5) subunit of the receptor. This compound was developed at the University of Bristol.

Excerpted from Wikipedia’s “UBP-302” article, available under the CC BY-SA 4.0 licence.

Available in 7 languages

via Wikidata sitelinks · CC0